title: Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells.
abstract: Different primings with DNA and fowlpox virus (FP) recombinants or FP alone were used in a pre-clinical trial to evaluate and compare immunogenicity and efficacy against HIV/SHIV. Three immunization regimens were tested in three groups of mice in which the SIV gag/pol and HIV-1 env transgenes were separately expressed by DNA and FP vectors, followed by VLP(SHIV) boosting. All of the protocols were effective in eliciting homologous neutralizing antibodies, although the mice immunized with DNA followed by FP recombinants or DNA+FP recombinants showed both high titres of neutralizing antibodies and high frequencies of env-specific IFNgamma-producing T lymphocytes. Vaccine efficacy, as demonstrated by growth control of env-expressing tumours, was obtained in both of these two groups of mice. These results establish a preliminary profile for the combined use of these recombinant vectors in protocols to be tested in the SHIV-macaque model of HIV-1 infection.
authors.affiliation: Department of Pharmacological Sciences, University of Milan, 20133 Milan, Italy. Antonia.Radaelli@unimi.it
authors.forename: Antonia
authors.initials: A
authors.lastname: Radaelli
authors.forename: Olivia
authors.initials: O
authors.lastname: Bonduelle
authors.forename: Paola
authors.initials: P
authors.lastname: Beggio
authors.forename: Brice
authors.initials: B
authors.lastname: Mahe
authors.forename: Eleana
authors.initials: E
authors.lastname: Pozzi
authors.forename: Veronica
authors.initials: V
authors.lastname: Elli
authors.forename: Manuela
authors.initials: M
authors.lastname: Paganini
authors.forename: Carlo
authors.initials: C
authors.lastname: Zanotto
authors.forename: Carlo
authors.initials: C
authors.lastname: De Giuli Morghen
authors.forename: Béhazine
authors.initials: B
authors.lastname: Combadière
mesh_terms: D016915:AIDS Vaccines / Q000235:genetics / Q000276:immunology*; D000818:Animals; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002522:Chlorocebus aethiops; D004274:DNA, Recombinant; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005587:Fowlpox virus / Q000235:genetics / Q000276:immunology*; D015686:Gene Products, env / Q000235:genetics / Q000276:immunology*; D015483:HIV Antibodies / Q000097:blood*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D007117:Immunization, Secondary; D007371:Interferon-gamma / Q000096:biosynthesis*; D051379:Mice; D008856:Microscopy, Fluorescence; D009369:Neoplasms / Q000473:pathology; D009500:Neutralization Tests; D013601:T-Lymphocytes / Q000276:immunology*; D014611:Vaccination; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology*; D022701:Virosomes / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D004274:DNA, Recombinant; D015686:Gene Products, env; D015483:HIV Antibodies; D019444:Vaccines, DNA; D022701:Virosomes; D007371:Interferon-gamma